Is Skyrizi Overtaking Humira? How the Immunology Market is Shifting
•
5 min read
According to AbbVie's financial reports in late 2024, the interleukin-23 inhibitor Skyrizi officially surpassed the TNF-alpha inhibitor Humira in quarterly and annual sales, marking a major market shift. This directly answers the question, is Skyrizi overtaking Humira?, and signals a new era in the treatment of autoimmune conditions.
